Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00124527 · ClinicalTrials.gov registry record · Phase 2

Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer

A Phase 2 study of Thyroid Cancer, sponsored by Eisai.

Completed
Registry status
Phase 2
Development phase
35
Enrollment target
10
Study locations

NCT00124527 is a Phase 2 study of Thyroid Cancer that has completed, run by Eisai. The registered enrollment target is 35 participants, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00124527, a Phase 2 study of Thyroid Cancer, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 2
Development phase
35 participants
Enrollment target
10
Study locations

Study Summary

Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroid cancer.

Conditions Studied

Thyroid Cancer

Interventions

  • DRUG Irofulven + capecitabine

Study Locations (10)

Other

  • - Salta
  • - Lyon
  • - Toulouse
  • - Villejuif
  • - Lima
  • - Moscow
  • - Obninsk
  • - Kiev

Colorado

  • - Aurora

Ohio

  • - Columbus

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2005-03-31
Est. Completion 2006-08-31
Phase Phase 2

Sponsor

Eisai

287 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00124527

The ClinicalTrials.gov registry entry for NCT00124527 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Irofulven + capecitabine is the first listed.

NCT00124527 reports 10 study locations spanning 3 distinct geographic areas - top geographies include Other, Colorado, Ohio.

Frequently Asked Questions

What is clinical trial NCT00124527 about?

NCT00124527 is a clinical study titled "Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer". Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroi...

What is the current status of trial NCT00124527?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2005-03-31. Estimated completion is 2006-08-31.

What conditions does trial NCT00124527 study?

This clinical trial studies the following conditions: Thyroid Cancer.

What interventions are being tested in trial NCT00124527?

The interventions under investigation include: Irofulven + capecitabine (DRUG).

Who is sponsoring clinical trial NCT00124527?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00124527 being conducted?

This trial has 10 study locations across Colorado, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thyroid Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.